Association of thiazolidinedione with a lower risk of Parkinson’s disease in a population with newly-diagnosed diabetes mellitus

References

• de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525–535.
   PubMed Web of Science ®Google Scholar
• Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999;46:598–605.
   PubMed Web of Science ®Google Scholar
• Hirsch EC. Glial cells and Parkinson's disease. J Neurol. 2000;247(Suppl 2):II58–II62.
   PubMedGoogle Scholar
• Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8:382–397.
   PubMed Web of Science ®Google Scholar
• Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci. 1993;69:125–130.
   PubMedGoogle Scholar
• Lu L, Fu DL, Li HQ, et al. Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS One. 2014;9:e85781.
   PubMed Web of Science ®Google Scholar
• Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care. 2011;34:2614–2623.
   PubMed Web of Science ®Google Scholar
• Hu G, Jousilahti P, Bidel S, et al. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care. 2007;30:842–847.
   PubMed Web of Science ®Google Scholar
• Yakubu-Madus FE, Stephens TW, Johnson WT. Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes Obes Metab. 2000;2:155–163.
   PubMed Web of Science ®Google Scholar
• Breidert T, Callebert J, Heneka MT, et al. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem. 2002;82:615–624.
   PubMed Web of Science ®Google Scholar
• Dehmer T, Heneka MT, Sastre M, et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem. 2004;88:494–501.
   PubMed Web of Science ®Google Scholar
• Hunter RL, Choi DY, Ross SA, et al. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett. 2008;432:198–201.
   PubMed Web of Science ®Google Scholar
• Schintu N, Frau L, Ibba M, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci. 2009;29:954–963.
   PubMed Web of Science ®Google Scholar
• Swanson CR, Joers V, Bondarenko V, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation. 2011;8:91.
   PubMed Web of Science ®Google Scholar
• Brauer R, Bhaskaran K, Chaturvedi N, et al. Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study. PLoS Med. 2015;12:e1001854.
   PubMed Web of Science ®Google Scholar
• Brakedal B, Flones I, Reiter SF, et al. Glitazone use associated with reduced risk of Parkinson's disease. Mov Disord. 2017;32:1594–1599.
   PubMed Web of Science ®Google Scholar
• Investigators. NN-P. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015;14:795–803.
   PubMed Web of Science ®Google Scholar
• Connolly JG, Bykov K, Gagne JJ. Thiazolidinediones and Parkinson Disease: A Cohort Study. Am J Epidemiol. 2015;182:936–944.
   PubMed Web of Science ®Google Scholar
• De Pablo-Fernandez E, Sierra-Hidalgo F, Benito-León J, et al. Association between Parkinson’s disease and diabetes: Data from NEDICES study. Acta Neurol Scand. 2017;136:732–736.
   PubMed Web of Science ®Google Scholar
• Segura-Aguilar J, Kostrzewa RM. Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update. Neurotox Res. 2015;27:328–354.
   PubMed Web of Science ®Google Scholar
• Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med. 2013;19:176–186.
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Limousin P, Lees A, et al. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain. 2013;136:374–384.
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–1675.
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Leeper TC, Carroll RT. mitoNEET as a novel drug target for mitochondrial dysfunction. Drug Discov Today. 2014;19:1601–1606.
   PubMed Web of Science ®Google Scholar
• Morris JK, Zhang H, Gupte AA, et al. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 2008;1240:185–195.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao W, Li G, et al. Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic Neurons In Vivo and In Vitro in Parkinson's Disease. PPAR Res. 2017;2017:4089214.
   PubMed Web of Science ®Google Scholar
• Athauda D, Foltynie T. Insulin resistance and Parkinson’s disease: A new target for disease modification? Prog Neurobiol. 2016;145-146:98–120.
   PubMed Web of Science ®Google Scholar